ACOTEC SCIENTIFIC HOLDINGS LIMITED Acotec Scientific Holdings Limited Stock
Equities
6669
KYG0096M1096
Medical Equipment, Supplies & Distribution
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.89 HKD | +0.58% |
|
+11.67% | -38.92% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 567M 78.62M 615M | Sales 2025 * | 699M 96.79M 757M | Capitalization | 1.98B 274M 2.15B |
|---|---|---|---|---|---|
| Net income 2024 * | 85M 11.78M 92.12M | Net income 2025 * | 121M 16.77M 131M | EV / Sales 2024 * | 2.69 x |
| Net cash position 2024 * | 453M 62.81M 491M | Net cash position 2025 * | 518M 71.83M 562M | EV / Sales 2025 * | 2.09 x |
| P/E ratio 2024 * |
22.6
x | P/E ratio 2025 * |
15.8
x | Employees | 638 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 13.04% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.58% | ||
| 1 week | +11.67% | ||
| Current month | +11.67% | ||
| 1 month | -3.64% | ||
| 3 months | -17.98% | ||
| 6 months | -44.35% | ||
| Current year | -38.92% |
1 week
5.91
6.90
1 month
5.807.38
Current year
5.8011.46
1 year
5.8017.00
3 years
4.2119.88
5 years
4.2119.88
10 years
4.2119.88
| Managers | Title | Age | Since |
|---|---|---|---|
Jing Li
CEO | Chief Executive Officer | 53 | 20-12-02 |
Weijia Li
CTO | Chief Tech/Sci/R&D Officer | 47 | 21-01-28 |
| Chief Operating Officer | 55 | 20-12-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hong Ni
BRD | Director/Board Member | 52 | 21-07-31 |
Kin Yee Poon
BRD | Director/Board Member | 52 | 21-01-28 |
Arthur Butcher
BRD | Director/Board Member | 53 | 23-02-08 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-06 | 6.89 | +0.58% | 20 000 |
| 24-05-06 | 6.85 | +6.86% | 293,000 |
| 24-05-03 | 6.41 | -2.58% | 276,133 |
| 24-05-02 | 6.58 | +6.65% | 343,000 |
| 24-04-30 | 6.17 | -2.06% | 306,000 |
Delayed Quote Hong Kong S.E., May 06, 2024 at 10:02 pm EDT
More quotes
Acotec Scientific Holdings Ltd is a China-based interventional medical device company. The Company focuses on interventional treatment of vascular diseases, involving Drug-coated Balloons (DCB) and Percutaneous Transluminal Angioplasty Balloon Catheter (PTA) etc. The Company has established a product portfolio for five major therapeutic areas, including vascular surgery, cardiology, nephrology, neurology and andrology. The Company's business covers China, Asia, Europe and other countries and regions.
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
6.316
CNY
Average target price
9.773
CNY
Spread / Average Target
+54.73%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -38.92% | 257M | |
| +73.17% | 12.39B | |
| -15.87% | 8.08B | |
| +17.74% | 7.25B | |
| +10.58% | 5.35B | |
| +33.33% | 4.63B | |
| -19.09% | 4.19B | |
| -35.55% | 2.44B | |
| +2.35% | 2.07B | |
| +9.66% | 1.88B |
- Stock Market
- Equities
- 6669 Stock